The Optimization Myth

The wellness industry has built a compelling narrative: your hormones are declining, your vitality is declining with them, and replacing what you've lost will restore who you were. Pellet clinics, testosterone optimization programs, and hormone "balancing" protocols have grown into a substantial industry on the back of this idea. It sounds physiologically plausible. The evidence doesn't support it.

Hormones are not youth in a syringe. Age-related changes in testosterone, estrogen, and thyroid function are real — but the assumption that reversing those changes restores youthful health is not. I see the results of this regularly: patients who have been on pellets or compounded regimens for months, at doses well outside physiologic ranges, who don't feel better. Some feel worse. Clinical trials consistently show that hormone therapy works well for specific, documented deficiencies. Treating levels that are low-normal, or chasing supraphysiologic targets, rarely produces the promised benefits and carries risks the optimization narrative rarely mentions.

The most important claim to address directly: neither testosterone replacement nor menopausal hormone therapy has been shown in randomized trials to extend lifespan or slow aging when used for that purpose.

📊 The Evidence — Does Hormone Therapy Extend Life?

The American College of Physicians explicitly recommends against initiating testosterone therapy to improve energy, vitality, physical function, or cognition in men with age-related low testosterone, citing very little or no benefit for these outcomes.[1] A pooled analysis of RCTs did show fewer deaths in testosterone-treated men (0.4% vs. 1.5%), but the ACP concluded the evidence was insufficient to draw conclusions about mortality — trials were not powered for this endpoint, event rates were low, and men at highest risk were excluded.[1] A comprehensive review concluded that neither the consequences of low testosterone nor the magnitude of treatment benefits justify broadly applied testosterone replacement in older men with low levels.[2]

For menopausal hormone therapy, the Women's Health Initiative 18-year follow-up found no increase or decrease in all-cause mortality (HR 0.99).[3] A 2026 Danish nationwide cohort study of 876,805 women found similarly neutral results (adjusted HR 0.96), with modest reductions at 3–10 years of use.[5] The USPSTF systematic review concluded that while MHT was not associated with increased mortality, current evidence does not confirm beneficial effects on cardiovascular disease, mortality, or dementia.[4]

One observational study using UK Biobank data found MHT was associated with a 0.17–0.25 year smaller biological aging discrepancy — which the authors estimated could translate to approximately 2% decreased mortality risk.[6] This finding will likely circulate in optimization circles. It is a retrospective observational study using surrogate markers, not clinical outcomes. The authors themselves call for further investigation before drawing clinical conclusions.

Your Body Regulates Hormones for a Reason

Every major hormonal system operates within a feedback loop. The hypothalamic-pituitary axis acts as the body's thermostat: when hormone levels rise, the brain signals the glands to produce less; when they fall, production ramps back up. These loops exist precisely to keep hormones within the narrow ranges where they're effective and safe — not as a lower bound to be escaped, but as a carefully calibrated operating window.

Introducing hormones from outside overrides that feedback. The body responds by suppressing its own production. This is why exogenous testosterone shuts down testicular function, why prolonged thyroid replacement can suppress the gland's natural output, and why abruptly stopping hormone therapy after extended use can produce significant withdrawal. The feedback loop is not a design flaw to be worked around. Disrupting it without a clear clinical reason — or pushing levels past the physiologic range in the name of optimization — has consequences. Each set in this series covers what those consequences look like in practice.

My Synthesis When I prescribe hormone therapy, I'm working with the body's physiology — restoring levels that have fallen below a threshold where function is genuinely impaired. I'm not pushing past the upper end of normal. That distinction matters for whether treatment works and for whether it's safe.

The Symptom Overlap Problem

The symptoms most commonly attributed to hormonal problems — fatigue, low energy, weight gain, poor concentration, mood changes — are among the least specific symptoms in medicine. They point in every direction at once. Sleep disorders, depression, anemia, and metabolic disease are far more common causes than any hormonal condition, and the numbers make that clear.

70%
of people with normal thyroid function have at least one "hypothyroid" symptom [10]
>25%
of men with unequivocally normal testosterone levels still report fatigue [9]
~4%
of persistent fatigue cases in primary care have any organic cause, including thyroid disease [8]

A population-based study of over 2,800 participants found that obesity, insomnia, depression, and anemia were each independently associated with fatigue — while TSH showed no independent association after adjusting for those factors.[7] The landmark European Male Aging Study found that after controlling for age, only sexual symptoms had a reliable relationship with low testosterone; fatigue and low energy did not.[9] The full evidence behind these findings — and what should actually drive the decision to test — is covered in detail in each set below.

⚠ The Cost of the Wrong Workup An extensive hormonal workup in a patient with normal labs doesn't just fail to find the answer — it often delays finding one. Sleep disorders, depression, and metabolic disease all require their own evaluation. Every month spent chasing a hormonal explanation is a month those conditions go unaddressed.

When Hormone Therapy Genuinely Helps

To be direct: hormone therapy is among the most effective treatments in medicine when the indication is right. The evidence is excellent. It just points to specific conditions and specific symptoms — not to optimization of levels within the normal range.

Thyroid replacement is highly effective for documented hypothyroidism. The picture gets more complicated with subclinical disease and the wellness industry's fixation on “optimal” TSH targets. There is also a black box warning on levothyroxine specifically prohibiting its use for weight loss — a myth covered directly in that set. All of it is in Set 1: Thyroid →

Testosterone therapy produces well-documented improvements in libido, erectile function, bone density, and muscle mass in men with confirmed hypogonadism. The evidence in women is narrower: the only well-supported indication is hypoactive sexual desire disorder, not fatigue or general wellbeing. Gender-affirming care for trans men and a direct look at the low-T industry are also in Set 2: Testosterone →

Menopausal hormone therapy reduces hot flash frequency by approximately 75% and severity by 87% in women with moderate to severe vasomotor symptoms — more effective than any nonhormonal alternative. For most healthy women without contraindications, it is my first-line recommendation, not a last resort. The risk-benefit story was badly distorted by the initial reading of the Women’s Health Initiative, and understanding what that trial actually showed matters enormously. Non-hormonal alternatives, vaginal estrogen (which has a fundamentally different safety profile from systemic MHT — including for breast cancer survivors), and gender-affirming care for trans women are all in Set 3: Estrogen & Progesterone →

Set 1 · 4 Posts

Thyroid

How the HPT axis works, when replacement is indicated, hyperthyroidism, and the myths the wellness industry sells.
Set 2 · 5 Posts

Testosterone

Hypogonadism in men and women, gender-affirming care for trans men, and a direct look at the low-T industry.
Set 3 · 5 Posts

Estrogen & Progesterone

The menopause transition, hormone therapy after WHI, non-hormonal options, and gender-affirming care for trans women.

One treatment worth flagging here that surprises many patients: vaginal estrogen for genitourinary symptoms after menopause has a safety profile that is fundamentally different from systemic hormone therapy — including for breast cancer survivors. The FDA recently removed the boxed warning from vaginal estrogen products, acknowledging this distinction. It's covered in detail in Set 3, but it's worth knowing upfront that "I can't use hormones" and "I can't use vaginal estrogen" are often not the same statement.

Hormones are essential to health — they govern metabolism, reproduction, stress response, bone density, and much more. But they operate within clearly defined ranges for good reason, and those ranges reflect where they're both effective and safe. Treating documented deficiency works. Pushing levels past the upper end of normal, or treating values that fall within the normal range, rarely produces the intended benefits — and often introduces risks that weren't part of the original problem.